Details of the Drug Combination

General Information of Drug Combination (ID: DCGW0W9)

Drug Combination Name
Vinblastine Sorafenib
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs Vinblastine   DM5TVS3 Sorafenib   DMS8IFC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: UACC62
Zero Interaction Potency (ZIP) Score: 4.16
Bliss Independence Score: 4.41
Loewe Additivity Score: 4.39
LHighest Single Agent (HSA) Score: 8.42

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vinblastine
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [2]
Anterior urethra cancer N.A. Approved [2]
Extragonadal germ cell tumor N.A. Approved [2]
Gestational trophoblastic neoplasia 2F33-2F76 Approved [2]
Kaposi sarcoma 2B57 Approved [2]
Mycosis fungoides 2B01 Approved [2]
Posterior urethra cancer N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Testicular cancer 2C80 Approved [2]
Testicular germ cell tumor N.A. Approved [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
Vinblastine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta-2 chain (TUBB2) TTJ2PTI TBB2A_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Vinblastine Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [8]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Vinblastine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [15]
------------------------------------------------------------------------------------
Vinblastine Interacts with 201 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [16]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [17]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Transport [18]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [19]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Increases Phosphorylation [20]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [21]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [22]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Stability [23]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [24]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [25]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Stability [23]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [24]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [20]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [25]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [25]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [26]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Affects Localization [22]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4) OTTDCUAO NFAC4_HUMAN Decreases Localization [27]
Transcriptional regulator QRICH1 (QRICH1) OTPVAX04 QRIC1_HUMAN Increases Phosphorylation [28]
Sorting nexin-10 (SNX10) OT05B7BT SNX10_HUMAN Affects Response To Substance [6]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Affects Response To Substance [6]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Affects Response To Substance [6]
Friend leukemia integration 1 transcription factor (FLI1) OT0EV3LX FLI1_HUMAN Affects Response To Substance [6]
Sulfotransferase 1A1 (SULT1A1) OT0K7JIE ST1A1_HUMAN Affects Response To Substance [6]
Histone H3-like centromeric protein A (CENPA) OT0NEJ4X CENPA_HUMAN Affects Response To Substance [6]
DNA polymerase zeta catalytic subunit (REV3L) OT0OP8EJ REV3L_HUMAN Affects Response To Substance [6]
Rab11 family-interacting protein 1 (RAB11FIP1) OT0T71OW RFIP1_HUMAN Affects Response To Substance [6]
Oxysterol-binding protein-related protein 10 (OSBPL10) OT0TFMBE OSB10_HUMAN Affects Response To Substance [6]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13) OT0UOKIT NDUAD_HUMAN Affects Response To Substance [6]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [6]
Lamin-B1 (LMNB1) OT100T3P LMNB1_HUMAN Affects Response To Substance [6]
Borealin (CDCA8) OT17D55D BOREA_HUMAN Affects Response To Substance [6]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Response To Substance [29]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Affects Response To Substance [6]
m7GpppX diphosphatase (DCPS) OT1FZVC9 DCPS_HUMAN Affects Response To Substance [6]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1) OT2E7A6W KANK1_HUMAN Affects Response To Substance [6]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [6]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25) OT2MR6O2 SNR25_HUMAN Affects Response To Substance [6]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Affects Response To Substance [6]
N-acetylglucosamine-1-phosphotransferase subunits alpha/beta (GNPTAB) OT2Z03OB GNPTA_HUMAN Affects Response To Substance [6]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Affects Response To Substance [6]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Affects Response To Substance [6]
Chromosome-associated kinesin KIF4A (KIF4A) OT3UWL7D KIF4A_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Response To Substance [6]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Affects Response To Substance [6]
c-Myc-binding protein (MYCBP) OT4IZR4R MYCBP_HUMAN Affects Response To Substance [6]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Affects Response To Substance [6]
Transcription termination factor 2 (TTF2) OT5LJOWM TTF2_HUMAN Affects Response To Substance [6]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Affects Response To Substance [6]
Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A) OT6285L4 FKB1A_HUMAN Affects Response To Substance [6]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Affects Response To Substance [6]
Electron transfer flavoprotein subunit beta (ETFB) OT6Q6FBD ETFB_HUMAN Affects Response To Substance [6]
Flap endonuclease 1 (FEN1) OT6QGG7O FEN1_HUMAN Affects Response To Substance [6]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [6]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [6]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [30]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Affects Response To Substance [6]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Affects Response To Substance [6]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Affects Response To Substance [6]
Pirin (PIR) OT8ALXHU PIR_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 alpha subcomplex subunit 7 (NDUFA7) OT8CV3H5 NDUA7_HUMAN Affects Response To Substance [6]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Response To Substance [6]
Replication protein A 14 kDa subunit (RPA3) OT8JAQGL RFA3_HUMAN Affects Response To Substance [6]
Deoxyribose-phosphate aldolase (DERA) OT8SMO3N DEOC_HUMAN Affects Response To Substance [6]
NADH dehydrogenase iron-sulfur protein 6, mitochondrial (NDUFS6) OT9IOONQ NDUS6_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 subunit C2 (NDUFC2) OT9M119L NDUC2_HUMAN Affects Response To Substance [6]
Beta-glucuronidase (GUSB) OT9N1DK3 BGLR_HUMAN Affects Response To Substance [6]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Affects Response To Substance [6]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [6]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [6]
Cysteine-rich PDZ-binding protein (CRIPT) OTA6M8M4 CRIPT_HUMAN Affects Response To Substance [6]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Affects Response To Substance [6]
ATP synthase subunit e, mitochondrial (ATP5ME) OTADVEE2 ATP5I_HUMAN Affects Response To Substance [6]
Transmembrane protein 14A (TMEM14A) OTANQA6G TM14A_HUMAN Affects Response To Substance [6]
MAP kinase-activated protein kinase 5 (MAPKAPK5) OTAZHPVK MAPK5_HUMAN Affects Response To Substance [6]
Shootin-1 (SHTN1) OTB07MOG SHOT1_HUMAN Affects Response To Substance [6]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Affects Response To Substance [6]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Affects Response To Substance [6]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [6]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Affects Response To Substance [6]
Probable ATP-dependent RNA helicase DDX23 (DDX23) OTBJHS8C DDX23_HUMAN Affects Response To Substance [6]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Affects Response To Substance [6]
Transmembrane protein 134 (TMEM134) OTBX9H9D TM134_HUMAN Affects Response To Substance [6]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Affects Response To Substance [6]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Affects Response To Substance [6]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Affects Response To Substance [6]
Cytoskeleton-associated protein 2 (CKAP2) OTCLTC0J CKAP2_HUMAN Affects Response To Substance [6]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [6]
Tetraspanin-13 (TSPAN13) OTCS9BZY TSN13_HUMAN Affects Response To Substance [6]
S-phase kinase-associated protein 2 (SKP2) OTD5B41X SKP2_HUMAN Affects Response To Substance [6]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1) OTDCSPXH SUCA_HUMAN Affects Response To Substance [6]
Proteasome activator complex subunit 4 (PSME4) OTDGF53O PSME4_HUMAN Affects Response To Substance [6]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [6]
Superkiller complex protein 8 (SKIC8) OTDSQYDN SKI8_HUMAN Affects Response To Substance [6]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [6]
Geminin (GMNN) OTDYKNIY GEMI_HUMAN Affects Response To Substance [6]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7) OTE0EG10 EFCB7_HUMAN Affects Response To Substance [6]
Vitamin K-dependent gamma-carboxylase (GGCX) OTE0FNAP VKGC_HUMAN Affects Response To Substance [6]
ATP synthase subunit f, mitochondrial (ATP5MF) OTE4TBG9 ATPK_HUMAN Affects Response To Substance [6]
Maternal embryonic leucine zipper kinase (MELK) OTEY2UQA MELK_HUMAN Affects Response To Substance [6]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Affects Response To Substance [6]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [6]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [6]
Exosome complex component RRP45 (EXOSC9) OTFKB37F EXOS9_HUMAN Affects Response To Substance [6]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [6]
High mobility group protein B2 (HMGB2) OTGEGAOK HMGB2_HUMAN Affects Response To Substance [6]
Phospholipid-transporting ATPase ABCA3 (ABCA3) OTH6MSKQ ABCA3_HUMAN Decreases Response To Substance [31]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [6]
Transmembrane protein 156 (TMEM156) OTH7YJID TM156_HUMAN Affects Response To Substance [6]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Affects Response To Substance [6]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Affects Response To Substance [6]
Catalase (CAT) OTHEBX9R CATA_HUMAN Affects Response To Substance [6]
Kinesin-like protein KIF11 (KIF11) OTHRGLCQ KIF11_HUMAN Affects Response To Substance [6]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Affects Response To Substance [6]
U6 snRNA-associated Sm-like protein LSm7 (LSM7) OTHZ2XPX LSM7_HUMAN Affects Response To Substance [6]
Kinesin-like protein KIF1B (KIF1B) OTI1XQTO KIF1B_HUMAN Affects Response To Substance [6]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [6]
Protein Mis18-beta (OIP5) OTI5C2DE MS18B_HUMAN Affects Response To Substance [6]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [6]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Affects Response To Substance [6]
Baculoviral IAP repeat-containing protein 7 (BIRC7) OTITCGHB BIRC7_HUMAN Decreases Response To Substance [32]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 subunit C1, mitochondrial (NDUFC1) OTJ5TNHB NDUC1_HUMAN Affects Response To Substance [6]
Low molecular weight phosphotyrosine protein phosphatase (ACP1) OTJ9CKLU PPAC_HUMAN Affects Response To Substance [6]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Affects Response To Substance [6]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [6]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH) OTJDOL20 HCDH_HUMAN Affects Response To Substance [6]
Lysophosphatidic acid receptor 1 (LPAR1) OTJNJQPF LPAR1_HUMAN Affects Response To Substance [6]
Kinesin-like protein KIF15 (KIF15) OTJRJEXL KIF15_HUMAN Affects Response To Substance [6]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Affects Response To Substance [6]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Affects Response To Substance [6]
Gamma-glutamylcyclotransferase (GGCT) OTKAICP5 GGCT_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Response To Substance [6]
Origin recognition complex subunit 6 (ORC6) OTKQN3KP ORC6_HUMAN Affects Response To Substance [6]
Sideroflexin-1 (SFXN1) OTL66767 SFXN1_HUMAN Affects Response To Substance [6]
Lamina-associated polypeptide 2, isoform alpha (TMPO) OTL68EL4 LAP2A_HUMAN Affects Response To Substance [6]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Increases Response To Substance [29]
Striatin (STRN) OTLOZL5I STRN_HUMAN Affects Response To Substance [6]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2) OTMZD4PW SUCB1_HUMAN Affects Response To Substance [6]
Protein downstream neighbor of Son (DONSON) OTN5HE0W DONS_HUMAN Affects Response To Substance [6]
Cytochrome c oxidase subunit 6B1 (COX6B1) OTNKXYQI CX6B1_HUMAN Affects Response To Substance [6]
Keratinocyte-associated transmembrane protein 2 (C5ORF15) OTO126A1 KCT2_HUMAN Affects Response To Substance [6]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Affects Response To Substance [33]
tRNA (TRMT5) OTOAZBPD TRM5_HUMAN Affects Response To Substance [6]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Affects Response To Substance [6]
Cytochrome c oxidase subunit 5A, mitochondrial (COX5A) OTP0961M COX5A_HUMAN Affects Response To Substance [6]
DNA fragmentation factor subunit beta (DFFB) OTPBW5N5 DFFB_HUMAN Affects Response To Substance [6]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [6]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [6]
Kazrin (KAZN) OTPM7BYM KAZRN_HUMAN Affects Response To Substance [6]
G2 and S phase-expressed protein 1 (GTSE1) OTPP742Z GTSE1_HUMAN Affects Response To Substance [6]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Affects Response To Substance [6]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [6]
Ornithine decarboxylase antizyme 1 (OAZ1) OTPT0PKZ OAZ1_HUMAN Affects Response To Substance [6]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [6]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Affects Response To Substance [34]
Pentraxin-related protein PTX3 (PTX3) OTPXHRKU PTX3_HUMAN Affects Response To Substance [6]
Ran-specific GTPase-activating protein (RANBP1) OTQE226K RANG_HUMAN Affects Response To Substance [6]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Affects Response To Substance [6]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [6]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1) OTQRET2B S5A1_HUMAN Affects Response To Substance [6]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Affects Response To Substance [6]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [6]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Affects Response To Substance [6]
Olfactory receptor 1I1 (OR1I1) OTRFD8BH OR1I1_HUMAN Affects Response To Substance [6]
Protein CREG1 (CREG1) OTRHJ8HK CREG1_HUMAN Affects Response To Substance [6]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Affects Response To Substance [6]
Kinetochore protein NDC80 homolog (NDC80) OTS7D306 NDC80_HUMAN Affects Response To Substance [6]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [6]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Affects Response To Substance [6]
Inhibin beta A chain (INHBA) OTSP64PQ INHBA_HUMAN Affects Response To Substance [6]
Leucine-rich repeat-containing protein 1 (LRRC1) OTSVD30Q LRRC1_HUMAN Affects Response To Substance [6]
NADH dehydrogenase flavoprotein 2, mitochondrial (NDUFV2) OTSZF7D6 NDUV2_HUMAN Affects Response To Substance [6]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [6]
Rho GTPase-activating protein SYDE1 (SYDE1) OTTIAF4D SYDE1_HUMAN Affects Response To Substance [6]
Isocitrate dehydrogenase , mitochondrial (IDH2) OTTQA4PB IDHP_HUMAN Affects Response To Substance [6]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Response To Substance [6]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Affects Response To Substance [6]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Response To Substance [6]
Transcription factor IIIA (GTF3A) OTVROUVQ TF3A_HUMAN Affects Response To Substance [6]
ATP-binding cassette sub-family A member 2 (ABCA2) OTVSYK0X ABCA2_HUMAN Decreases Response To Substance [31]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Affects Response To Substance [6]
Serine/threonine-protein kinase 26 (STK26) OTW4QE0D STK26_HUMAN Affects Response To Substance [6]
Homer protein homolog 1 (HOMER1) OTWFD3SI HOME1_HUMAN Affects Response To Substance [6]
Acyl-coenzyme A thioesterase 13 (ACOT13) OTWRUST1 ACO13_HUMAN Affects Response To Substance [6]
Divergent protein kinase domain 1A (DIPK1A) OTWS5V2I DIK1A_HUMAN Affects Response To Substance [6]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Affects Response To Substance [6]
Hematopoietic lineage cell-specific protein (HCLS1) OTX7WGYN HCLS1_HUMAN Affects Response To Substance [6]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15) OTX8SZOT NUD15_HUMAN Affects Response To Substance [6]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3) OTXL10N9 NDUA3_HUMAN Affects Response To Substance [6]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [6]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Affects Response To Substance [6]
Condensin complex subunit 2 (NCAPH) OTXOS97C CND2_HUMAN Affects Response To Substance [6]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Affects Response To Substance [6]
Protein FAN (NSMAF) OTYNVZ23 FAN_HUMAN Affects Response To Substance [6]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Response To Substance [6]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2) OTZ092ZJ THIC_HUMAN Affects Response To Substance [6]
G-protein coupled receptor 176 (GPR176) OTZ8PL9B GP176_HUMAN Affects Response To Substance [6]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [6]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 201 DOT(s)
Indication(s) of Sorafenib
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [4]
Carcinoma 2A00-2F9Z Approved [4]
Clear cell renal carcinoma N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
Medullary thyroid gland carcinoma N.A. Approved [4]
Non-small-cell lung cancer 2C25.Y Approved [4]
Renal cell carcinoma 2C90 Approved [5]
Thyroid cancer 2D10 Approved [4]
Hepatocellular carcinoma 2C12.02 Phase 3 [5]
Myelodysplastic syndrome 2A37 Phase 2 [5]
Sorafenib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [40]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [40]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [41]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [40]
------------------------------------------------------------------------------------
Sorafenib Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [42]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [43]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [44]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [45]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [46]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [45]
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [47]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Sorafenib Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [48]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [49]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [50]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [50]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [48]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [51]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Sorafenib Interacts with 112 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [52]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Response To Substance [53]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Phosphorylation [54]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [55]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [56]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [56]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [57]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [58]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [58]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Decreases Expression [35]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [35]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [35]
GTPase NRas (NRAS) OTVQ1DG3 RASN_HUMAN Decreases Expression [35]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [35]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [35]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Decreases Expression [35]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [35]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [35]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [35]
Cyclin-dependent kinase 9 (CDK9) OT2B7OGB CDK9_HUMAN Decreases Expression [35]
Growth factor receptor-bound protein 2 (GRB2) OTOP7LTE GRB2_HUMAN Decreases Expression [35]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [35]
Interferon regulatory factor 5 (IRF5) OT8SIIAP IRF5_HUMAN Increases Expression [35]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [35]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [35]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [35]
Histone deacetylase 6 (HDAC6) OT9W9MXQ HDAC6_HUMAN Decreases Expression [35]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [56]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [59]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Decreases Expression [60]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Decreases Expression [36]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Ubiquitination [61]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B) OTL9I7LO GA45B_HUMAN Increases Expression [62]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [37]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [63]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [60]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Activity [64]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [65]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [66]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [67]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Decreases Activity [54]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [68]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [62]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [69]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [70]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Phosphorylation [60]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Activity [71]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Expression [67]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [72]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [64]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [52]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [73]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [36]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Activity [74]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Activity [75]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Phosphorylation [76]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [56]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [77]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [78]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [79]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [79]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [73]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [80]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Decreases Phosphorylation [54]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Decreases Phosphorylation [75]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [81]
Signal transducer and activator of transcription 5A (STAT5A) OTBSJGN3 STA5A_HUMAN Decreases Activity [82]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [83]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [65]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Decreases Phosphorylation [65]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Decreases Phosphorylation [65]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [64]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [84]
CCAAT/enhancer-binding protein delta (CEBPD) OTNBIPMY CEBPD_HUMAN Increases Expression [63]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [83]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [85]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [86]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [87]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [69]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Increases Expression [67]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Increases Expression [88]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [89]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [90]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [73]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Decreases Phosphorylation [75]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Cleavage [60]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [60]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [91]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [92]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [77]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Phosphorylation [93]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Decreases Expression [94]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [38]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Decreases Expression [95]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Decreases Expression [60]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [96]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [38]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [64]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1) OT50NR57 PINK1_HUMAN Increases Expression [61]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [37]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [97]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [98]
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD) OT37FKH0 CYLD_HUMAN Increases Expression [55]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [94]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [37]
E3 ubiquitin-protein ligase TRIM62 (TRIM62) OT15YO6N TRI62_HUMAN Affects Response To Substance [99]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Response To Substance [60]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Affects Response To Substance [53]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Decreases Response To Substance [100]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Affects Response To Substance [53]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Increases Response To Substance [89]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Response To Substance [101]
------------------------------------------------------------------------------------
⏷ Show the Full List of 112 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCQJ6UE CAOV3 Investigative [1]
Adenocarcinoma DC3N6DP A427 Investigative [1]
Adenocarcinoma DCDS8AV NCIH2122 Investigative [1]
Adenocarcinoma DC7P7DY NCIH23 Investigative [1]
Adenocarcinoma DC023Z8 NCIH520 Investigative [1]
Adenocarcinoma DCVE6UB COLO320DM Investigative [1]
Adenocarcinoma DCDAOTZ DLD1 Investigative [1]
Adenocarcinoma DCXEWDG HCT116 Investigative [1]
Adenocarcinoma DCH033B SW-620 Investigative [1]
Amelanotic melanoma DCXX7ZN A2058 Investigative [1]
Chronic myelogenous leukemia DCKKPBC KBM-7 Investigative [1]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCL5AVV ES2 Investigative [1]
Large cell lung carcinoma DCFMFIN NCI-H460 Investigative [1]
Malignant melanoma DCZMEC9 A375 Investigative [1]
Malignant melanoma DCBTUV6 HT144 Investigative [1]
Malignant melanoma DCNWFPX SKMEL30 Investigative [1]
Mesothelioma DCUIOGM MSTO Investigative [1]
Non small cell carcinoma DC1IS6S SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DCS903P A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCI2VFY SK-OV-3 Investigative [1]
Prostate carcinoma DCJ9AN9 LNCAP Investigative [1]
Prostate carcinoma DCLWKZ0 VCAP Investigative [1]
Breast and ovarian cancer syndrome DC21CRB UWB1289 Investigative [102]
Breast and ovarian cancer syndrome DCA3BEA UWB1289+BRCA1 Investigative [102]
Breast carcinoma DCCGGN5 ZR751 Investigative [102]
Breast carcinoma DC4DGIL KPL1 Investigative [102]
Breast carcinoma DCKBARM OCUBM Investigative [102]
Carcinoma DCKWEQ2 OV90 Investigative [102]
Colon adenocarcinoma DCCQ5LR LOVO Investigative [102]
Colon carcinoma DC2KHHW RKO Investigative [102]
Invasive ductal carcinoma DC1MS1D T-47D Investigative [102]
Rectal adenocarcinoma DCD7AVE SW837 Investigative [102]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Vinblastine FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
4 Sorafenib FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
6 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
7 Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
8 Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
9 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
10 Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
11 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
12 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
13 Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
14 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
15 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
16 Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 2005 Sep;272(18):4725-40.
17 MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
18 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
19 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
20 Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
21 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
22 Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
23 Cytoskeletal architecture differentially controls post-transcriptional processing of IL-6 and IL-8 mRNA in airway epithelial-like cells. Exp Cell Res. 2006 May 15;312(9):1496-506. doi: 10.1016/j.yexcr.2006.01.010. Epub 2006 Feb 24.
24 Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
25 Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
26 Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL. Mol Cell Biochem. 2001 Sep;225(1-):7-20. doi: 10.1023/a:1012203110027.
27 Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol. 2007 Jan;210(1):246-56. doi: 10.1002/jcp.20861.
28 Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
29 E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
30 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
31 Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006 Aug;5(8):1986-94.
32 Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007 May;64(9):1137-44. doi: 10.1007/s00018-007-6510-7.
33 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526.
34 c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol. 2008;29(5):287-303. doi: 10.1159/000156706. Epub 2008 Sep 19.
35 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
36 Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro. 2014 Jun;28(4):552-61. doi: 10.1016/j.tiv.2014.01.002. Epub 2014 Jan 13.
37 The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007 Aug;27(15):5499-513. doi: 10.1128/MCB.01080-06. Epub 2007 Jun 4.
38 Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.
39 Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 2018 Sep;51:74-82. doi: 10.1016/j.tiv.2018.04.010. Epub 2018 Apr 24.
40 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
41 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
42 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
43 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
44 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
45 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
46 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
47 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
48 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
49 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
50 Drug Interactions Flockhart Table
51 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
52 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
53 The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
54 Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
55 Down-regulation of CYLD as a trigger for NF-B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2011 Jan;38(1):121-31.
56 Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011 Aug 1;82(3):216-26. doi: 10.1016/j.bcp.2011.04.011. Epub 2011 May 13.
57 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
58 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer. 2012 Sep 10;12:402.
59 The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
60 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
61 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
62 Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.
63 Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.
64 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
65 Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
66 Sorafenib inhibits transforming growth factor 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011 May;53(5):1708-18. doi: 10.1002/hep.24254.
67 Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
68 Sorafenib is an antagonist of the aryl hydrocarbon receptor. Toxicology. 2022 Mar 30;470:153118. doi: 10.1016/j.tox.2022.153118. Epub 2022 Feb 3.
69 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
70 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. doi: 10.1158/0008-5472.CAN-07-1473.
71 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30.
72 Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
73 Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7.
74 Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.
75 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.
76 Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.
77 Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.
78 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
79 Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
80 Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways. Chem Biol Interact. 2023 Jan 25;370:110329. doi: 10.1016/j.cbi.2022.110329. Epub 2022 Dec 22.
81 Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem. 2011 Jul;46(7):2845-51. doi: 10.1016/j.ejmech.2011.04.007. Epub 2011 Apr 14.
82 The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007 Sep;72(3):788-95. doi: 10.1124/mol.106.033308. Epub 2007 Jun 26.
83 Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
84 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.
85 The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
86 Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 2015 Feb;143(2):374-84. doi: 10.1093/toxsci/kfu235. Epub 2014 Nov 3.
87 Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther. 2009 Oct;8(20):1904-13. doi: 10.4161/cbt.8.20.9436. Epub 2009 Oct 6.
88 Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019 Sep 15;379:114665. doi: 10.1016/j.taap.2019.114665. Epub 2019 Jul 16.
89 Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.
90 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20;24(46):6861-9. doi: 10.1038/sj.onc.1208841.
91 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
92 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
93 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005 Oct 28;3:39. doi: 10.1186/1479-5876-3-39.
94 GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11;283(2):726-32. doi: 10.1074/jbc.M705343200. Epub 2007 Nov 8.
95 Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep;5(9):2378-87. doi: 10.1158/1535-7163.MCT-06-0235.
96 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
97 Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
98 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
99 TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-B pathway. Toxicol Appl Pharmacol. 2022 Jun 15;445:116035. doi: 10.1016/j.taap.2022.116035. Epub 2022 Apr 23.
100 Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma. Food Chem Toxicol. 2020 Aug;142:111475. doi: 10.1016/j.fct.2020.111475. Epub 2020 Jun 6.
101 Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells. Toxicol Appl Pharmacol. 2020 Sep 1;402:115117. doi: 10.1016/j.taap.2020.115117. Epub 2020 Jul 4.
102 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.